422 related articles for article (PubMed ID: 20888703)
1. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
3. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Fokas E; Conradi L; Weiss C; Sprenger T; Middel P; Rau T; Dellas K; Kitz J; Rödel F; Sauer R; Rüschoff J; Beissbarth T; Arnold D; Ghadimi BM; Rödel C; Liersch T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):992-9. PubMed ID: 24210078
[TBL] [Abstract][Full Text] [Related]
4. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
5. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.
Hong YS; Kim DY; Lim SB; Choi HS; Jeong SY; Jeong JY; Sohn DK; Kim DH; Chang HJ; Park JG; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1171-8. PubMed ID: 20605355
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K; Treschl A; Mai S; Barreto-Miranda M; Kienle P; Ströbel P; Erben P; Woernle C; Dinter D; Kähler G; Hochhaus A; Post S; Willeke F; Wenz F; Hofheinz RD;
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1487-93. PubMed ID: 19131187
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
9. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Eisterer W; De Vries A; Öfner D; Rabl H; Koplmüller R; Greil R; Tschmelitsch J; Schmid R; Kapp K; Lukas P; Sedlmayer F; Höfler G; Gnant M; Thaler J;
Anticancer Res; 2014 Nov; 34(11):6767-73. PubMed ID: 25368289
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
11. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
[TBL] [Abstract][Full Text] [Related]
12. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Sun PL; Li B; Ye QF
Int J Colorectal Dis; 2012 Oct; 27(10):1325-32. PubMed ID: 22430888
[TBL] [Abstract][Full Text] [Related]
13. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
14. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
15. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
16. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.
Cai G; Zhu J; Palmer JD; Xu Y; Hu W; Gu W; Cai S; Zhang Z
Radiat Oncol; 2015 Feb; 10():57. PubMed ID: 25889149
[TBL] [Abstract][Full Text] [Related]
17. Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
Gollins S; West N; Sebag-Montefiore D; Myint AS; Saunders M; Susnerwala S; Quirke P; Essapen S; Samuel L; Sizer B; Worlding J; Southward K; Hemmings G; Tinkler-Hundal E; Taylor M; Bottomley D; Chambers P; Lawrie E; Lopes A; Beare S
Br J Cancer; 2017 Oct; 117(9):1286-1294. PubMed ID: 28859058
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
[TBL] [Abstract][Full Text] [Related]
19. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
[TBL] [Abstract][Full Text] [Related]
20. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
Ballonoff A; Kavanagh B; McCarter M; Kane M; Pearlman N; Nash R; Shah RJ; Raben D; Schefter TE
Am J Clin Oncol; 2008 Jun; 31(3):264-70. PubMed ID: 18525306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
